1231 related articles for article (PubMed ID: 16821613)
1. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
2. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
[TBL] [Abstract][Full Text] [Related]
3. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
Antila R; Jalkanen J; Heikinheimo O
Gynecol Oncol; 2006 Apr; 101(1):97-101. PubMed ID: 16278010
[TBL] [Abstract][Full Text] [Related]
4. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.
Olawaiye A; Caesar L; Walsh D; Lyman M; Yeh J; Rodabaugh K; Marchetti D; Lele S; Odunsi K
Gynecol Oncol; 2004 Sep; 94(3):796-802. PubMed ID: 15350375
[TBL] [Abstract][Full Text] [Related]
6. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
7. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
8. Abdominal carcinomatosis in women with a history of breast cancer.
Garg R; Zahurak ML; Trimble EL; Armstrong DK; Bristow RE
Gynecol Oncol; 2005 Oct; 99(1):65-70. PubMed ID: 15979132
[TBL] [Abstract][Full Text] [Related]
9. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.
Ayhan A; Guvenal T; Salman MC; Ozyuncu O; Sakinci M; Basaran M
Gynecol Oncol; 2005 Aug; 98(2):235-41. PubMed ID: 15982725
[TBL] [Abstract][Full Text] [Related]
10. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
[TBL] [Abstract][Full Text] [Related]
11. Management of bilateral breast carcinoma: long-term results.
Goksel HA; Yagmurdur MC; Karakayali H; Moray G; Demirhan B; Isiklar I; Bilgin N; Haberal M
Int Surg; 2004; 89(3):166-71. PubMed ID: 15521255
[TBL] [Abstract][Full Text] [Related]
12. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
[TBL] [Abstract][Full Text] [Related]
14. Ovarian metastases from breast cancer: report of 29 cases.
Bigorie V; Morice P; Duvillard P; Antoine M; Cortez A; Flejou JF; Uzan S; Darai E; Barranger E
Cancer; 2010 Feb; 116(4):799-804. PubMed ID: 20041486
[TBL] [Abstract][Full Text] [Related]
15. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
16. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
17. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
[TBL] [Abstract][Full Text] [Related]
18. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
[TBL] [Abstract][Full Text] [Related]
20. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
